$3.84
▲ +0.3% Today
as of Sep 4, 16:51 ET
Last 30 days
Recent Press Releases & News
Larimar: Q2 Earnings Snapshot
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy
Overview
52-week range
$2.71
$6.42
30% of range
Avg surprise (last 3)
+14.9%
Avg reaction (last 2)
+2.9%
50% positive
Latest IV / EM
589%
EM ±95.3% · $5 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 14, 2026 | Mar/2026 | $-0.31 | $-0.53 | +41.5% | +32.6% | -5.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.61 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.41 | $-0.47 | +12.8% | — | — | earnings |
| Wed Apr 30, 2025 | Mar/2025 | $-0.46 | $-0.42 | -9.5% | — | +10.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.24 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.34 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.27 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.21 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.19 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.15 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-34M | $-31M | — | $-49M | $-28M | $-31M | — | $-18M |
| Net income | $-33M | $-30M | — | $-48M | $-26M | $-29M | — | $-15M |
| EPS (diluted) | — | — | — | $-0.61 | $-0.41 | $-0.46 | — | $-0.24 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $93M | $178M | $85M | $90M | $21M | $21M | $33M | $35M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $161M | $205M | $142M | $183M | $146M | $165M | $195M | $213M |
| Total assets | $165M | $209M | $146M | $187M | $150M | $170M | $200M | $219M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $38M | $50M | $68M | $48M | $30M | $26M | $28M | $21M |
| Total equity | $127M | $158M | $78M | $139M | $120M | $144M | $172M | $198M |